Class summary at a glance.

Every drug in the Estrogen class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 21tracked in Part D
CY24 Part D spend: $973.4Mcombined across class
Total Rx claims: 8.9M3.9M unique beneficiaries
Generic mfrs (active): 54across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Estradiol

Brand: Climara · 8.0M Part D claims (CY24) · 3.6M beneficiaries · First FDA approval: 1994-12-22

21 generic mfrs 171 plans require PA

Low NADAC$0.059

→

Avg plan cost$19.50

Part D spend $605.7M 329× spread, current vs floor

Class share

62%

of class CY24 spend

View profile →

Estrogens, Conjugated

Brand: Conjugated Estrogens · 897K Part D claims (CY24) · 383K beneficiaries · First FDA approval: 2004-09-01

1 generic mfrs 95 plans require PA

Low NADAC$5.24

→

Avg plan cost$6.51

Part D spend $367.7M 1× spread, current vs floor

Class share

38%

of class CY24 spend

View profile →

Conjugated Estrogens

Brand: Premarin · — Part D claims (CY24) · First FDA approval: 1956-12-01

Brand-only (no generics) 0 plans require PA

Low NADAC$15.10

→

Avg plan cost$15.10

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Conjugated Estrogens and Bazedoxifene

Brand: Duavee · — Part D claims (CY24) · First FDA approval: 2013-10-03

Brand-only (no generics) 22 plans require PA

Low NADAC$6.49

→

Avg plan cost$6.49

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Conjugated Estrogens and Medroxyprogesterone

Brand: Premphase · — Part D claims (CY24) · First FDA approval: 2009-09-21

Brand-only (no generics) 186 plans require PA

Low NADAC$8.68

→

Avg plan cost$8.69

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Drospirenone and Estradiol

Brand: Angeliq · — Part D claims (CY24) · First FDA approval: 2005-11-28

1 generic mfrs 0 plans require PA

Low NADAC$6.36

→

Avg plan cost$6.37

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Estradiol Gel

Brand: Estradiol · — Part D claims (CY24) · First FDA approval: 2022-10-01

Brand-only (no generics) 0 plans require PA

Low NADAC$1.18

→

Avg plan cost$1.44

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Estradiol Transdermal

Brand: Estradiol · — Part D claims (CY24) · First FDA approval: 2024-07-15

Brand-only (no generics)

Low NADAC$1.18

→

Avg plan cost$1.44

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Estradiol and Norethindrone

Brand: ABIGALE · — Part D claims (CY24) · First FDA approval: 2008-04-17

6 generic mfrs 140 plans require PA

Low NADAC$0.659

→

Avg plan cost$0.699

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Estradiol and Norethindrone Acetate Transdermal System

Brand: CombiPatch (estradiol/norethindrone acetate transdermal system) · — Part D claims (CY24) · First FDA approval: 1998-08-07

Brand-only (no generics) 0 plans require PA

Low NADAC$31.82

→

Avg plan cost$31.83

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Estradiol and Progesterone

Brand: Bijuva · — Part D claims (CY24) · First FDA approval: 2019-04-03

Brand-only (no generics) 10 plans require PA

Low NADAC$8.13

→

Avg plan cost$8.28

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Etonogestrel and Ethinyl Estradiol

Brand: EluRyng · — Part D claims (CY24) · First FDA approval: 2019-12-16

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$50.04

→

Avg plan cost$76.50

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Etonogestrel and Ethinyl Estradiol Vaginal

Brand: EnilloRing · — Part D claims (CY24) · First FDA approval: 2023-08-15

Brand-only (no generics) 0 plans require PA

Low NADAC$50.04

→

Avg plan cost$50.04

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Etonogestrel and Ethinyl Estradiol Vaginal Ring

— Part D claims (CY24) · First FDA approval: 2023-11-01

Brand-only (no generics)

Low NADAC$50.04

→

Avg plan cost$50.04

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Junel Fe

— Part D claims (CY24) · First FDA approval: 2021-10-06

Brand-only (no generics)

Low NADAC$0.204

→

Avg plan cost$0.204

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Levonorgestrel and Ethinyl Estradiol

Brand: ALTAVERA · — Part D claims (CY24) · First FDA approval: 2001-04-02

Brand-only (no generics) 0 plans require PA

Low NADAC$0.112

→

Avg plan cost$2.98

Part D spend — 26× spread, current vs floor

Class share

of class CY24 spend

View profile →

Norelgestromin and Ethinly Estradiol

— Part D claims (CY24) · First FDA approval: 2021-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Norelgestromin and Ethinyl Estradiol

Brand: XULANE · — Part D claims (CY24) · First FDA approval: 2014-04-16

4 generic mfrs 0 plans require PA

Low NADAC$32.38

→

Avg plan cost$35.12

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Norethindrone and Ethinyl Estradiol

Brand: ALYACEN 1/35 · — Part D claims (CY24) · First FDA approval: 2001-06-06

17 generic mfrs 40 plans require PA

Low NADAC$0.128

→

Avg plan cost$0.410

Part D spend — 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Norethindrone and Ethinyl Estradiol and Ferrous

Brand: AUROVELA Fe · — Part D claims (CY24) · First FDA approval: 2003-09-18

Brand-only (no generics) 0 plans require PA

Low NADAC$0.128

→

Avg plan cost$0.799

Part D spend — 6× spread, current vs floor

Class share

of class CY24 spend

View profile →

Segesterone and Ethinyl Estradiol

Brand: Annovera · — Part D claims (CY24) · First FDA approval: 2024-08-16

Brand-only (no generics) 0 plans require PA

Low NADAC$2317.31

→

Avg plan cost$2317.31

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.